Newsletter des essais clinique en #hematologie CHU de Nice ARS Paca #innovation #LAM #LAL #myelome #lymphome #SMD #SMP #LMC

How I treat transplant-eligible patients with myelofibrosis ashpublications.org/blood/article-… #mpnsm

Venetoclax (VEN) Improves Response Rates but Not Survival in Patients with #CMML Treated with Hypomethylating Agents (HMA) ash.confex.com/ash/2023/webpr… #ASH23

Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival ash.confex.com/ash/2023/webpr… #ASH23

Causes and consequences of clonal hematopoiesis loom.ly/yyCzyFE #hematopoiesisandstemcells #myeloidneoplasia #reviewarticles #reviewseries

Weekend review 📖 What is the right duration of VENETOCLAX with HMA for AML: 7 days vs 14 days vs 21 days or 28 days? Brief review of literature in this 🧵 #leusm #AML

Es hoy!!!! No te lo pierdas victor salinas Sofia Grille Marcelo Iastrebner XimeVT Alicia Enrico

Excelente encuentro!!

Diplomado "Hematología para médicos no especialistas" 👀👀❤️❤️ Hospital Del Salvador Servicio de Salud Metropolitano Oriente (SSMO) Medichi U.Chile medichi.uchile.cl/diploma-hemato…

New drugs in myelofibrosis onlinelibrary.wiley.com/doi/epdf/10.10…

So satisfying to watch live the #ODAC meeting (at 4 AM Kyoto 🇯🇵 time where I am at #MDSsm meeting) & see vast majority of panel recognize the benefits over risks of #imetelstat based on our pivotal #IMerge trial, & look forward to having the drug approved for our patients!

👀👀 Nuestro Diploma Hematología para médicos no especialistas... con mucho cariño y esfuerzo. Más info👇

Very impressive overview of European and international cooperative clinical trials in #MDSsm at #ESHMDS2024 ESH (Haematology) in #EMSCO with a great panel discussion by top leaders in the field

Gracias a todos los que participaron presencial y virtualmente #ASH2024 #latam María Díez Campelo G Garcia-Manero XimeVT Ximena Jordan Bruno Roberto Ovilla Martinez Alicia Enrico Marcelo Iastrebner

Este 11 de marzo nos juntamos para hablar de SMD de alto riesgo y las opciones terapéuticas para pacientes refractarios y recaídos con el Dr. Adolfo de la Fuente MD Anderson Cancer Center Alicia Enrico XimeVT #SMD #ALTORIESGO. No dejes de participar!

Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a practical guide to diagnosis and management pubmed.ncbi.nlm.nih.gov/40253543/

Excited to share our latest article published in Blood Cancer Journal Blood Cancer Journal from Hokkaido Leukemia Net regarding duration of Venetoclax in AZA-VEN for AML patient. nature.com/articles/s4140…

Treatment Algorithm: This is the algorithm we have used during our discussion with Andrew Kuykendall MD on Polycythemia Vera and Essential Thrombocythemia! #OncTwitter #MedTwitter #HemeTwitter OncUpdates

🚨 AML 1st-line Tx Algorithm (ASCO 2025) 🔹 Assess: age, comorbidities, PS, chemo/radiotx exposure 🔹 Profile: morphology, immunophenotype, cytogenetics, molecular 👩‍⚕️ Eligible for intensive chemo CBF-AML ➝ chemo ➕ gemtuzumab FLT3 mut ➝ chemo ➕ FLT3i t-AML / AML-MRC ➝

🧬 AML study (2010–2024, n=187): 1️⃣ TDT groups: 1–5d (70%), 6–10d (16%), 11+d (14%) 2️⃣ CR ↓ with 11+d delay (OR=0.32, p=0.003) 3️⃣ No OS difference on multivariate analysis 📌 Waiting for full profiling before induction is safe